Scientists have long thought that HIV's tendency to lay dormant within a person for 10 years or more was due to the behavior of the cells it infects or an error in the disease’s programming, but new evidence suggests that this inactivity may be an evolutionary strategy to help the virus to survive and spread.
International Business Times
Los Angeles Times
Early research by Dr. Katherine Pollard identified many regions of the human genome that appear to be evolving quickly. New research suggests these areas are responsible for differentiating human brains from chimpanzee brains.
NPR All Things Considered
Dr. Katherine Pollard says it's easy to find genetic differences between humans and chimpanzees, but it's hard to know precisely what these differences are doing. In Dr. Pollard's lab, scientists are exploring human and chimp DNA with stem cells in a dish and are using genome engineering to study the effects of these differences.
Dr. Katherine Pollard comments on new research that investigates how super-evolving parts of our genome differentiated our brains from chimpanzees'. Dr. Pollard was one of the first researchers to identify these special genome sequences, dubbed "human-accelerated regions."
ABC 7 News
Dr. Sheng Ding is working to develop a drug that can convert energy-storing white fat into calorie-burning brown fat. He says this could help improve weight loss and treat obesity or diabetes.
This month, the Gladstone Institutes in San Francisco reported a chemical trick that substantially increases the efficiency of gene editing using CRISPR technology.
A new paper in the Journal of Neuroscience from scientists at the Gladstone Institutes and the University of California, San Francisco describes how manipulating levels of a protein associated with memory can stave off Alzheimer’s symptoms, even in the presence of the disease-causing toxins.
It’s been over a year since The FDA approved Truvada, a once a day medication that prevents HIV infection. But why are so few people taking it? Dr. Robert Grant talks about the drug and why it’s slow to catch on.
San Francisco Business Times